Latest news with #SBX
Time Business News
23-07-2025
- Business
- Time Business News
The Next Frontier in Single-Cell Genomics
Single-cell genome sequencing is a powerful technique that enables the analysis of full genetic material from individual cells, allowing researchers to highlight genetic variations, mutation and cellular inequality that which wholesale sequencing is often missed. The market for this technique is growing rapidly, due to the increasing demand for accurate medicine, cancer research, and immune profiles, technological progress in microfluidics, the next generation sequencing, and AI-operated data analysis, as well as making single-cell workflow more scalable, cost-purpose and clinically relevant. Key Growth Drivers and Opportunities rising Demand for Accurate and Personalized Medicine: Increasing demand for accurate and personalized drugs is a major driver of single-cell genome sequencing market, as this technique allows for detailed genetic analysis at the individual cell level-important to identify drugs goals and treatment reactions. Especially by enabling accurate diagnostics and sequential therapy in oncology, immunology and neurology, the single-cell sequencing supports more effective, changes towards patient-specific medical interventions, fueling its adoption in research and clinical settings. Challenges Despite its rapid growth, the single-cell genome sequencing faces several borders in the market, including the high cost of equipment and reagents, complex sample preparation protocols, and large-scale, data interpretations due to the noise dataset include challenges. Additionally, limited standardization in platforms and analytical devices may obstruct fertility and scalability, especially in clinical applications. These factors prohibit adoption widely, especially in low-resources settings and small research institutes. Innovation and Expansion Roche and Broad Clinical Labs Collaborate to Advance the Rollout of Next-Gen SBX Sequencing In May 2025, Roche and Broad Clinical Labs established a collaborative partnership to create and test innovative applications utilizing Roche's recently introduced Sequencing by Expansion (SBX) next-generation sequencing (NGS) technology. The goal of this partnership is to use SBX technology to revolutionize biomedical research and clinical genomics. Additionally, it will seek to make SBX technology a standard product for the research community at Broad Clinical Labs in terms of quick, scalable sequencing. Ultima Genomics' UG 100TM Platform Partnership Increases Access to Inexpensive DNA Sequencing Worldwide In February 2025, The UG100TM next-generation sequencing (NGS) platform's creator, Ultima Genomics, Inc., announced several new collaborations with top genomic services providers, expanding access to high-quality, reasonably priced DNA sequencing worldwide. In order to facilitate single cell sequencing, spatial transcriptomics, proteomics, whole genome sequencing, and other applications, this international network of renowned service providers will deliver industry-leading DNA sequencing services using the UG 100. The Ontario Institute of Cancer Research, Novogene, Psomagen, Eurofins, and Broad Clinical Labs are among the top-tier companies that were revealed today. These partners join the University of Minnesota Genomics Center, Macrogen, and Inocras as current Ultima Genomics service provider partners. Inventive Sparks, Expanding Markets Key players operating in the single-cell genome sequencing include ThermoFisher Scientific, Inc., Illumina, Bio-Rad, BD, Pacific Biosciences of California, Inc., QIAGEN, 10X Genomics, Inc., BGI, Novogene Co. Ltd., NuGEN Technologies, Inc., Takara Bio, Inc., F Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, Fludigim, and Agilent Technologies Inc. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
23-05-2025
- Business
- Yahoo
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche's SBX sequencing technology1, with an initial focus on critically ill newborns and their parents. Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease. This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research applications. Basel, 23 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche's recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab's research community. The first project will see Broad Clinical Labs using the SBX technology to advance research into trio-based whole genome sequencing of critically ill newborns and their biological parents. This program aims to establish a future state where whole genome sequencing becomes a routine component of clinical care in neonatal intensive care units (NICUs) —enabling precise, timely diagnoses and improved outcomes for infants with suspected genetic disorders. 'The SBX technology was designed with both clinical impact and scientific discovery in mind, and offers the next-generation of fast, scalable sequencing solutions,' said Matt Sause, CEO of Roche Diagnostics. 'Collaborating with Broad Clinical Labs, a leader in clinical genomics and omics research, accelerates our ability to deliver on that promise and support better outcomes for patients through cutting-edge genomic technology.' 'Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,' said Niall Lennon, Chair and CSO at Broad Clinical Labs. 'Together with Roche, we're aiming to demonstrate how fast, scalable, and high-quality sequencing can support both routine clinical care and drive biomedical innovation.' The SBX technology represents a significant leap forward in next-generation sequencing, offering ultra-fast turnaround times, exceptional scalability, and cost efficiency across a range of sequencing applications. The SBX technology has been tailored to deliver high-throughput performance with a flexible workflow that will support rapid deployment in time-sensitive settings like neonatal intensive care units (NICUs) and comprehensive multi-omic discovery research. The collaboration will also explore the capabilities of the SBX technology for RNA sequencing, including both bulk and single-cell approaches. These efforts will focus on leveraging the longer reads of the SBX technology to unlock novel molecular insights and data types that could reshape how researchers understand disease mechanisms and identify new therapeutic targets. Broad Clinical Labs is a wholly owned subsidiary of the Broad Institute of MIT and Harvard. Broad Institute researchers, who have led the field in the development and application of single cell methods across a range of biomedical areas, will be the early users to leverage the new system. The collaboration between Roche and Broad Clinical Labs reflects a shared vision of a genomics-enabled healthcare system and reinforces both organizations' commitment to advancing precision medicine at scale. About Sequencing by Expansion (SBX) technologyRoche's groundbreaking next-generation sequencing technology is designed to overcome the limitations of traditional sequencing methods. As well as high accuracy, it also offers an unparalleled combination of flexibility and speed, making it a versatile tool for a wide range of genomic applications. One of the key benefits of the SBX technology is its scalability. The chemistry is coupled with an advanced, high-throughput CMOS sensor module that enables ultra-rapid, real-time base calls and analysis. This module is designed to process numerous samples simultaneously, creating a highly scalable and flexible architecture for cost-efficient sequencing across different project sizes, from small-scale studies to large projects involving thousands of samples. This versatility makes the SBX technology suitable for a variety of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. As a result, it holds promise not only for research laboratories but also eventually for clinical settings where detailed genomic insights are crucial. With SBX technology, researchers can meet new and evolving research demands efficiently, paving the way for significant advances in our understanding of genetics and disease, ultimately contributing to better healthcare outcomes. The SBX chemistry was invented by Mark Kokoris and Robert McRuer who co-founded Stratos Genomics. Stratos Genomics was acquired by Roche in 2020. To find out more about Roche's novel SBX technology, click here. About Broad Clinical LabsBroad Clinical Laboratories was founded in 2013 as a subsidiary of Broad Institute, Inc. to accelerate the world toward a better understanding, diagnosis, and treatment of disease by pursuing projects, developing products, and driving adoption of cutting edge -omics technologies and novel molecular assays. Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 750,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. For more information, please visit About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by The SBX technology is in development and not commercially available. The content of this material reflects current study results or design goals. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment 23052025_SBX Broad Clinical Labs_enSign in to access your portfolio
Yahoo
20-02-2025
- Business
- Yahoo
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology Reducing the time from sample to genome from days to hours, this novel approach could significantly speed up genomic research, as well as translational and clinical applications in the years to come Basel, 20 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications. Next-generation sequencing provides detailed insights into genetics, genomics and cell biology. It has already improved our understanding of gene functions and interaction, and is critical to our ability to decode complex diseases such cancer, immune disorders, and neurodegenerative conditions, where hundreds or even thousands of genes impact disease progression. 'The science behind SBX technology represents a significant breakthrough that addresses the limitations of existing sequencing solutions,' states Matt Sause, CEO of Roche Diagnostics. 'By integrating and enhancing the two technologies, Roche's SBX has created a differentiated approach, offering unparalleled speed, efficiency and flexibility. The speed and accuracy of SBX has the potential to revolutionise the use of sequencing in research and healthcare.' SBX is a novel sequencing approach which uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer. Xpandomers, which are fifty times longer than the original molecule, encode the sequence information into high signal-to-noise reporters, meaning they provide clear signals with minimal background noise. This enables highly accurate single-molecule nanopore sequencing using a Complementary Metal Oxide Semiconductor (CMOS)-based sensor module with parallel processing capabilities, offering speed and flexibility beyond that of other sequencing technologies. 'Solving the signal-to-noise challenge is a key efficiency driver for the technology. With this capability we can flexibly operate across a range of throughput scales using the same sequencing system, which provides a significant advantage to users,' said Mark Kokoris, Head of Roche's SBX Technology. The ability of SBX technology to provide ultra-rapid, high-throughput, flexible and scalable sequencing lends itself to a broad range of projects and applications. This technology will enable researchers to make significant discoveries that enhance our understanding of diseases and their treatment, with the potential to drive greater adoption in the clinical lab setting in the future. About Sequencing by Expansion (SBX) technologyRoche's groundbreaking next-generation sequencing technology is designed to overcome the limitations of traditional sequencing methods. As well as high accuracy, it also offers an unparalleled combination of flexibility and speed, making it a versatile tool for a wide range of genomic applications. One of the key benefits of SBX technology is its scalability. The chemistry is coupled with an advanced, high-throughput CMOS sensor module that enables ultra-rapid, real-time base calls and analysis. This module is designed to process numerous samples simultaneously, creating a highly scalable and flexible architecture for cost-efficient sequencing across different project sizes, from small-scale studies to large projects involving thousands of samples. This versatility makes SBX technology suitable for a variety of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. As a result, it holds promise not only for research laboratories but also eventually for clinical settings where detailed genomic insights are crucial. With SBX technology, researchers can meet new and evolving research demands efficiently, paving the way for significant advances in our understanding of genetics and disease, ultimately contributing to better healthcare outcomes. SBX chemistry was invented by Mark Kokoris and Robert McRuer who co-founded Stratos Genomics. Stratos Genomics was acquired by Roche in 2020. To find out more about Roche's novel SBX technology, click here. About Roche's Sequencing PortfolioRoche has been committed to providing next-generation sequencing library prep solutions and application support for sequencing for several years. Today, next-generation sequencing solutions from Roche play an important role in the sequencing ecosystem. Our KAPA sample preparation products offer high-performance DNA, RNA library prep and target enrichment solutions for a variety of applications. Additionally, we offer the AVENIO Edge system that provides a true walk-away automated solution for many of our KAPA kits. This system does not require advanced programming skills and comes with ready-to-use kits and protocols. Our AVENIO assays offer robust solutions for oncology, including the recent approval of the AVENIO Tumor Tissue CGP Automated Kit, a collaboration between Roche and Foundation Medicine, two leaders in oncology. About RocheFounded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment 20250220_SBX Technology
